USPTO serial 79404288
CTGCT CENTRE FOR THE TECHNOLOGIES OF GENE AND CELL THERAPY
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Nov 4, 2025
- Examiner
- LEE, YATSYE ISADORA
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with CTGCT CENTRE FOR THE TECHNOLOGIES OF GENE AND CELL THERAPY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Jennifer Fraser
Jennifer Fraser Dykema Gossett PLLC1301 K Street, NW, Suite 1100 WestWashington, DC 20005United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | Chemicals for use in science; Chemical substances for analyses in laboratories, other than for medical or veterinary purposes; chemical materials, namely assays, reagents, and nucleic acids for use in gene and cell therapy research; Chemical preparations for scientific purposes; natural fertilisers; chemical products used in gene and cell therapy technologies, namely viral vectors, plasmids, and lipid nanoparticles for gene delivery; active chemical ingredients used in the manufacture of medicines for diseases and cancer | ACTIVE | — |
| 005 | Pharmaceuticals and medical preparations for the treatment of genetic diseases, neurodevelopmental diseases and cancers; Diagnostic preparations for medical purposes; cells for medical use; pharmaceutical and medical preparations used in gene and cell therapy technologies; pharmaceutical compounds, preparations, and medicines used in the treatment of genetic diseases, neurodevelopmental diseases, and cancers; pharmaceutical compounds, preparations, and medicines used in the treatment of genetic diseases and cancer | ACTIVE | — |
| 009 | Scientific, research, teaching and detecting apparatus and instruments, namely, microscopes, confocal laser microscopes, flow cytometers, bioreactors for cell culturing, cell sorters, and analytical systems composed of microscopes, spectrophotometers, luminometers, spectrofluorimeters, and computer hardware for analyzing cells; downloadable computer software for analyzing biological data, designing gene and cell therapies, and managing laboratory processes in the field of gene and cell therapy; scientific apparatus and instruments, namely, microscopes, confocal laser microscopes, flow cytometers, and bioreactors for cell culturing, and downloadable computer software for analyzing cell populations, designing viral vectors, and optimizing bioreactor processes used in gene and cell therapy technologies; scientific apparatus and instruments, namely, high-throughput confocal microscopes for kinetics measurements and in vivo imaging systems composed of micro CT, magnetic resonance imaging apparatus, not for medical purposes, for live animal imaging in gene and cell therapy research, and downloadable computer software for analyzing genetic sequences and modeling drug responses used in the treatment of diseases and cancer; Prerecorded USB flash drives featuring educational content on gene and cell therapy technologies and their applications in treating diseases and cancer | ACTIVE | — |
| 010 | Surgical and medical apparatus and instruments for use in gene therapy and cell therapy; surgical and medical apparatus and instruments used during medical and surgical procedures; medical apparatuses and instruments, namely, bioreactors, cell sorters, flow cytometers, and analytical systems composed of medical imaging apparatuses all of which provide cell and particle analysis, detection, or counting for medical, medical diagnostic, and therapeutic uses in the field of gene and cell therapy technologies; medical devices used in the treatment of genetic diseases and cancers | ACTIVE | — |
| 016 | Printed matter, namely, printed brochures, reports, and educational materials in the field of gene and cell therapy, advanced therapy medicinal products (ATMPs), and translational medicine; bookbinding tape; printed photographs; stationery and office requisites, namely, printed notepads; printed notebooks; printed journals related to gene and cell therapy technology; printed informational flyers related to the treatment of diseases and cancer | ACTIVE | — |
| 025 | Clothing, namely, lab coats, pants, shirts, t-shirts and headwear | ACTIVE | — |
| 041 | Education, namely, conferences, workshops, seminars, and online courses in the field of gene and cell therapy, advanced therapy medicinal products (ATMPs), and translational medicine and distribution of course material in connection therewith; publication of texts, providing online non-downloadable news articles in the field of gene and cell therapy, ATMPs, and translational medicine, and writing of texts, namely, writing of articles for professional journals other than for advertising or publicity; audio, video, and multimedia production, as well as photography; educational and teaching services, namely, workshops, seminars, conferences, online courses, and hands-on training in the field of gene and cell therapy, ATMPs, and translational medicine; organizing conferences, exhibitions, and competitions in the field of gene and cell therapy, ATMPs, and translational medicine; education, namely, conferences, workshops, seminars, and online courses in the field of gene and cell therapy technology; education, namely, workshops, seminars, and training programs in the treatment of diseases and cancer | ACTIVE | — |
| 042 | Scientific and technological services, namely, research and design in the fields of treatments for genetic diseases, neurodevelopmental diseases and cancers, and gene and cell therapy technology; industrial analysis, industrial research and industrial design services in the fields of treatments for genetic diseases, neurodevelopmental diseases and cancers, and gene and cell therapy technology; quality control and authentication services in the field of gene and cell therapy products; design and development of computer hardware and software; scientific laboratory services; biological and medical research laboratory services; laboratory services, namely, rental of laboratory apparatus and instruments; Research laboratory analysis services in the field of gene therapy, cell therapy, and synthetic biology; biological research, clinical research in the field of gene therapy and cell therapy for genetic diseases, neurodevelopmental diseases and difficult-to-treat cancers, and medical research; design and development of medical technology; development of new technologies for others in the field of gene and cell therapies; design and development of gene and cell therapy technology; scientific research for medical purposes in the field of diseases and cancer | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Kemijski institut
- Other trademarks owned by Kemijski institut
- Other trademarks owned by Kemijski institut
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 009
- Other trademarks in Class 010
- Other trademarks in Class 016
- Other trademarks in Class 025
- Other trademarks in Class 041
- Other trademarks in Class 042
- Similar marks named CTGCT CENTRE FOR THE TECHNOLOGIES OF GENE AND CELL THERAPY
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 28, 2026 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| May 12, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| May 12, 2026 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Feb 26, 2026 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Feb 11, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Feb 11, 2026 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Feb 4, 2026 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Nov 4, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Nov 4, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Sep 16, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Sep 16, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Sep 10, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Aug 14, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Aug 14, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Aug 13, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Aug 13, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 19, 2025 | RFNP | REFUSAL PROCESSED BY IB | — |
| Jun 23, 2025 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 13, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| May 13, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 13, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Dec 21, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Dec 2, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Dec 2, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Nov 16, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Nov 15, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 14, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Sep 16, 2024 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Sep 16, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 12, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |